Hedge Fund's Novel AIA Strategy Targets Acorda's MS Drug
An organization tied to hedge fund manager Kyle Bass on Tuesday filed a petition for review under the America Invents Act of the patent for Acorda Therapeutics Inc.'s multiple sclerosis drug...To view the full article, register now.
Already a subscriber? Click here to view full article